Nachfolgende Publikationen sind im Zusammenhang mit der BayImmuNet-Projektarbeit erschienen:
- Bourquin C., Wurzenberger C., Fuchs S., Anz D., Weigel S., Sandholzer N., Winter G., Coester C., Endres S.: Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response. In: Journal of Immunotherapy 2010; 339:935-44. JIF 4.8
- Zoglmeier C., Bauer H., Noerenberg D., Wedekind G., Bittner P., Sandholzer N., Rapp M., Anz D., Endres S., Bourquin C.: CpG blocks immune suppression by myeloid-derived suppressor cells in tumor-bearing mice. In: Clinical Cancer Research (2011); 17:1765-75. JIF 6.7
- Duewell P., Kisser U., Heckelsmiller K., Hoves S., Stoitzner P., Morelli AB., Koernig S., Clausen BE., Dauer M., Eigler A., Anz D., Bourquin C., Maraskovsky E., Endres S., Schnurr M.: ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. In:Journal of Immunology (2011); 187:55-63. JIF 5.6
- Anz D., Mueller W., Golic M., Kunz WG., Rapp M., Koelzer VH., Ellermeier J., Ellwart JW., Schnurr M., Bourquin C., Endres S.: CD103 is a hallmark of tumor-infiltrating regulatory T cells. In: International Journal of Cancer (2011); in press. JIF 4.7
- Bourquin C., Hotz C., Noerenberg D., Völkl A., Storch B., Sandholzer N., Wurzenberger C., Anz D., Endres S.: Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance. In: Cancer Research (2011); Epub ahead of print. JIF 7.5
- Loschko J., Schlitzer A., Dudziak D., Drexler I., Sandholzer N., Bourquin C., Reindl W., Krug AB.: Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cell-mediated immunity. In: J Immunol. 2011, 186:6718-25. Epub 2011 May 9.
- Anz D., Eiber S., Scholz C., Endres S., Kirchner T., Bourquin C., Mayr D.: In breast cancer a high ratio of tumor-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype. In: Histopathology 2011; in press.
- Dann A., Poeck H., Croxford A. L., Graupp S., Kierdorf K., Knust M., Pfeifer D., Maihoefer C., Endres S., Kalinke U., Meuth S. G., Weindl H., Knobleloch K-P., Akria S. Waisman A. Hartmann G., Prinz M. : Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. In: Nature Neuroscience 2011, 10.1038/2964.
- Schüller V., Heidegger S., Sandholzer N., Nickels Ph., Suhartha N., Endres S., Bourquin C., Liedl T.: Cellular Immunostimulation by CpGSequence-Coated DNA OrigamiStructures. In acsnano Vol. 5, No. 12, 9696–9702, 2011
- Diepolder H., Obst R.: Making antigen invisible: a coinhibitory molecule regulates the interaction between T cells and dendritic cells. In Expert Rev Vaccines 2010 Mar;9(3):243-7.
- Raziorrouh B., Ulsenheimer A., Schraut W., Heeg M., Kurktschiev P., Zachoval R., Jung M-C., Thime R., Neumann–Haefelin Ch., Horster S., Wächtler M., Spannagl M., Haas J., Diepolder H., Grüner N.H.: Inhibitory Molecules That Regulate Expansion and Restoration of HCV-Specific CD4+ T Cells in Patients With Chronic Infection. In: GASTROENTEROLOGY 2011;141:1422–1431.
- Diepolder H., Grüner N.: Evolution of cellular immune responses to hepatitis C virus during antiretroviral therapy and its clinical implications. In: Gut September 2010 Vol 59 No 9
- Edinger M., Hoffmann P.: Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. In: Current Opinion in Immunology 2011, 23:679–684
- Edinger M.: Regulatory T cells for the prevention of graft-versus-host disease: Professionals defeat amateurs. In: Eur. J. Immunol. 2009. 39: 2966–2968
- Hilgendorf I., Mueller-Hilke B., Kundt G., Holler E., Hoffmann P., Edinger M., Freund M., Wolff D.: The lack of memory B cells including T cell independent IgM+ IgD+ memory B cells in chronic graft-versus host disease is associated with susceptibility to infection. In: Transplant International; European Society for Organ Transplantation 25 (2012) 87–96
- Landfried K., Zhu W., Waldhier M. C., Schulz U., Ammer J., Holler B., Wolff D., Edinger M., Peter K., Kreutz M., Andreesen R., Oefner P. J., Holler E.: Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. In: blood 2011 118: 6971-6974
- Roll D., Ammer J., Holler B., Salzberger B., Schweiger B., Jilg W., Andreesen R., Edinger M., Wolff D., Holler E.: Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. In: Infection DOI 10.1007/s15010-011-0206-5
- Krug Ch., Schmidt P., Chmielewski M., Birkholz K., Schwenkert M., Fey G., Schuler-Thurner B., Gerold Schuler, Hinrich Abken, Dörrie J., Schaft N.: Retargeting T cells with MHC-Independent chimeric antigen receptors by RNA electroporation. In: Experimental Dermatology 2012, Volume 21, Issue 3, pp. e27 publiziert
- Khanna N., Stuehler C., Conrad B., Lurati S., Krappmann S., Einsele H., Berges C. and Topp M.S.: Generation of a multiple pathogen-specfic T-cell product for adoptiveimmunotherapy based on activation-dependent expression of CD154. In: blood (2010): 12-322610
- Stuehler C., Khanna N., Bozza S., Zelante T., Moretti S., Kruhm M., Lurati S., Conrad B., Worschech E., Stevanovic S., Krappmann S., Einsele H., Latgé JP., Loeffler J., Romani L. and Topp M.S.:Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. In: blood-(2010-12); 325084
- Lang V.R., Mielenz D., Neubert K., Böhm Ch., Schett G., Jäck H-M., Voll R.E., Meister S.: The Early Marginal Zone B Cell-Initiated T-Independent Type 2 Response Resists the Proteasome Inhibitor Bortezomib. In: J Immunol 2010;185;5637-5647;
- Meister S., Frey B., Lang V.R., Gaipl U. S., Schett G., Schlötzer-Schrehardt U., Voll R.E. : Calcium Channel Blocker Verapamil Enhances Endoplasmic Reticulum Stress and Cell Death Induced by Proteasome Inhibition in Myeloma Cells1,2. In: NEOPLASIA Volume 12 Number 7 July 2010 pp. 550–561
- Gomez A.M., Vrolix K., Martínez-Martínez P., Molenaar P.C., Phernambucq M., van der Esch E., Duimel H., Verheyen F., Voll R.E., Manz R. A., De Baets M.H., Losen M.: Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis. In: The Journal of Immunology 2011;186;2503-2513
- Polzer K., Neubert K., Meister S., Frey B., Baum W., Distler J.H.,Gückel E., Schett G., Voll R.E., Zwerina J.: Proteasome Inhibition Aggravates Tumor Necrosis Factor Mediated Bone Resorption in a Mouse Model of Inflammatory Arthritis. In: ARTHRITIS & RHEUMATISM
Vol. 63, No. 3, March 2011, pp 670–680 - Starke Ch., Frey S., Wellmann U., Urbonaviciute V., Herrmann M., Amann K., Schett G., Winkler Th., Voll R.E. : High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice. In:Eur. J. Immunol. 2011. 41: 2107–2112
- Woelfl M., Merker K., Morbach H., Van Gool S. W., Eyrich M., Greenberg Ph. D., Schlegel P.G.: Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. In: Cancer Immunol Immunother (2011) 60:173–186
- Wiegering V., Eyrich M., Rutkowski S., Woelfl M., Schlegel P.G., Winkler B.:TH1 predominance is associated with improved survival in pediatric medulloblastoma patients In: Cancer Immunol Immunother DOI (10.1007); s00262-011-0981-y
- Kronik N., Kogan Y., Schlegel P.G., Wölfl M.: Improving T-cell Immunotherapy for Melanoma Through a Mathematically Motivated Strategy: Efficacy in Numbers? In: J Immunother, Volume 35, Number 2, February–March 2012
